To access this content, you must purchase a Premium membership, or log in if you are a member.
TomoTherapy CEO is poised to get $4.7 million exit package
If shareholders and regulators approve Accuray's $277 million purchase of TomoTherapy, chief executive officer Fred Robertson will be out of a job, but he stands to gain an exit package worth $4.7 million. Plus, Robertson owns nearly 600,000 shares of TomoTherapy stock, worth about $2.75 million. Together, they total about $7.5 million for the physician and former anesthesiology professor turned businessman. (WISCONSIN STATE JOURNAL, 4/21)